REMARKS

The above preliminary amendment is made to remove multiple dependencies from claims 3-9.

A new abstract page is supplied to conform to that appearing on the publication page of the WIPO application, but the new Abstract is typed on a separate page as required by U.S. practice.

Applicants respectfully request that the preliminary amendment described herein be entered into the record prior to calculation of the filing fee and prior to examination and consideration of the above-identified application.

If a telephone conference would be helpful in resolving any issues concerning this communication, please contact Applicants' primary attorney-of record, Douglas P. Mueller (Reg. No. 30,300), at (612) 371.5237.

Respectfully submitted,

MERCHANT & GOULD P.C.
P.O. Box 2903
Minneapolis, Minnesota 55402-0903
(612) 332-5300

Dated: March 28, 2002

By _____
Douglas P. Mueller
Reg. No. 30,300

DPM:hb

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	TOJO et al.	Docket No.:	13357.4USWO
Serial No.:	unknown	Filed:	concurrent herewith
Int'l Appln No.:	PCTJP0006815	Int'l Filing Date:	September 29, 2000
Title:	OPHTHALMIC ADHESIVE PREPARATIONS FOR PERCUTANEAOUS ABSORPTION		

MARKUP COPY SHOWING THE CHANGES MADE

IN THE CLAIMS

Please amend claims 3-9 to read as follows:

3.(amended) The transdermal patch of claim 1 ~~or 2~~ wherein the percutaneous absorption enhancer is polyoxyethylene oleyl ether and/or isopropyl myristate.

4.(amended) The ophthalmic transdermal patch ~~of one~~ of ~~claims~~ claim 1 ~~to 3~~ wherein the content of polyoxyethylene oleyl ether in the drug-containing layer is 5-30 W/W%.

5.(amended) The ophthalmic transdermal patch ~~of one~~ of ~~claims 1 to 4~~ claim 3 wherein the content of isopropyl myristate in the drug-containing layer is 5-30 W/W%.

6.(amended) The ophthalmic transdermal patch ~~of one~~ of ~~claims~~ claim 1 ~~to 5~~ wherein the base matrix comprises acrylic adhesive, silicone elastomer or styrene-isoprene-styrene copolymer.

7.(amended) The ophthalmic transdermal patch ~~of one~~ of ~~claims 1 to 6~~ claim 3 wherein the ratio of the content by weight concentration (W/W%) of polyoxyethylene oleyl ether to isopropyl myristate is in the range of 1:0.1-1:5 in the drug-containing layer.

8.(amended) The ophthalmic transdermal patch ~~of one~~ of ~~claims~~ claim 1 ~~to 7~~ wherein the drug is a steroidal drug.

9.(amended) The ophthalmic transdermal patch ~~of one~~ of ~~claims~~ claim 1 ~~to 7~~ wherein the drug is a compound of the formula (1)